Millennium Management
NGNE icon

Millennium Management’s Neurogene NGNE Stock Holding History

Millennium Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,720
Closed -$359K – 7288
2021
Q4 		$359K Buy
+3,720
New +$453K ﹤0.01% 5351

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Millennium Management's NGNE Position: Q1 2026 in Review

Millennium Management increased its Neurogene (NGNE) stake by 187% in Q1 2026, buying an estimated $2.59M and bringing the position to 204,809 shares worth $4.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3164.

Millennium Management first reported a position in NGNE in Q3 2015 and has held it in 36 quarters since. The position peaked at $8.57M in Q1 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Millennium Management held 204,809 shares of Neurogene worth $4.13M as of Q1 2026.
  • Millennium Management bought 133,488 Neurogene shares in Q1 2026, an estimated $2.59M.
  • Neurogene made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3164 holding.
  • Millennium Management first reported a position in Neurogene in Q3 2015 and has held it in 36 quarters since.
  • Millennium Management's Neurogene position peaked at $8.57M in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.